Dr. Erik Sulman

Latest News
Diseases
Diseases & Conditions

Lung Cancer

Breast Cancer

Hematologic Malignancies

Genitourinary Cancers (GU)

Gynecologic Cancers

Glioma

Gastrointestinal Cancers (GI)
Discover local Gastrointestinal Cancers (GI) resources:

Select your city

Ann Arbor
Miami
Phoenix
Events
Our Mission
Physician Profiles

Latest News
Diseases
Diseases
- Lung Cancer
- Breast Cancer
- Hematologic Malignancies
- Genitourinary Cancers (GU)
- Gynecologic Cancers
- Glioma
- Gastrointestinal Cancers (GI)
  Discover local Gastrointestinal Cancers (GI) resources:
  
  Select your city
  
  Select your city
  
  Ann Arbor
  Miami
  Phoenix
Events
Our Mission
Physician Profiles
My Account
Sign In
Sign Up
Log Out
SurvivorNet.com

Back to Results

Dr. Erik Sulman

LOCATION OF PRACTICE

Duke University School Of Medicine

NPI Number

1922261171

ABOUT

Dr. Erik Sulman is a distinguished clinician and researcher with a robust background in the treatment of brain tumors and the development of novel therapeutic strategies. His research focuses on the molecular mechanisms of radiation resistance in glioblastoma and the development of targeted therapies to overcome these challenges. Additionally, he is involved in identifying molecular predictors of treatment response and improving the effectiveness of radiation therapy.

Is this you? Claim this Profile

Published Articles

(18)F-Fluciclovine for Detection of Recurrent Brain Metastases After Radiotherapy: Image Interpretation Criteria and Diagnostic Performance from the PURSUE Study.- 2026 Feb 25

Reply to: Blood-Brain Barrier Heterogeneity in NRG BN007: Implications for Immunotherapy Delivery.- 2026 Jan 16

Retrospective analysis of the impact of antidepressants with anti-acid sphingomyelinase activity on survival of patients with glioblastoma.- 2026 Jan 3

Neurocognitive outcomes in patients with brain metastases: a systematic review.- 2025 Dec

Genomic and Epigenomic Signatures Can Distinguish Aggressive Chromophobe Renal Cell Carcinoma from Indolent Renal Oncocytic Tumors in Clinical-grade Samples.- 2025 Dec

Hypofractionation of Gamma Knife Radiosurgery for Intracranial Meningiomas: A Retrospective Multicenter Study and Systematic Review of Literature.- 2025 Oct 27

Dual Immune Check Point Blockade in MGMT-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II/III Clinical Trial.- 2025 Sep 20

Persistent chromatin alterations and gene expression reprogramming follow widespread DNA damage in glioblastoma.- 2025 Jun 24

mtgRNA-db: An annotated database of multi-target CRISPR-Cas9 guide-RNAs in the human genome.- 2025 May 10

Outcomes of concurrent versus non-concurrent immune checkpoint inhibition with stereotactic radiosurgery for melanoma brain metastases.- 2025 Jul

Clinical Trials

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma

Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma

Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment

Terms of Use
Privacy Policy
Contact Us
Advertising Policy

Sign Up for SN Connect

Join SN Connect for access to the latest clinical tools, research updates, and expert insights across specialties

Personalized clinical content tailored to your specialty and patient demographics
Comprehensive treatment guides and case studies for evidence-based care
Real-time updates on therapeutic advancements and expert analyses
Decision support tools to enhance patient care
And more..

Already have an account? Sign In